Targeting signal transduction pathways for the treatment of Kaposi sarcoma

Janet Douglas, Henry B. Koon, Ashlee Moses

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Kaposi sarcoma (KS) is a multi-focal angioproliferative disease driven by infection of cells by Kaposi sarcoma herpesvirus/human herpesvirus-8 (KSHV/HHV8). KSHV/HHV8 infection activates numerous sequential and parallel signaling pathways creating an angiogenic-inflammatory state that leads to the development of Kaposi sarcoma. These pathways can be grouped into KSHV/HHV8-specific pathways and cellular growth/angiogenic pathways that are pirated by KSHV/HHV8. Advances in our understanding of the pathogenesis of KS parallel the clinical development of signal transduction inhibitors. This chapter reviews the signaling pathways active in KSHV/HHV8-infected cells and discusses the use of clinical inhibitors of these pathways in the treatment of KS.

Original languageEnglish (US)
Title of host publicationMolecular Basis for Therapy of AIDS-Defining Cancers
PublisherSpringer New York
Pages79-93
Number of pages15
ISBN (Print)9781441915122
DOIs
Publication statusPublished - 2010

    Fingerprint

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Douglas, J., Koon, H. B., & Moses, A. (2010). Targeting signal transduction pathways for the treatment of Kaposi sarcoma. In Molecular Basis for Therapy of AIDS-Defining Cancers (pp. 79-93). Springer New York. https://doi.org/10.1007/978-1-4419-1513-9_5